WilmerHale Advises Wellington Management in MBX Biosciences’ $115M Series B Financing

• 12.8.2022

On November 14, MBX Biosciences, a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, announced the closing of a $115 million Series B financing round led by Wellington Management, which was represented by WilmerHale. Additional funding was provided by RA Capital Management and Norwest Venture Partners along with existing investors Frazier Life Sciences, New Enterprise Associates (NEA) and OrbiMed.

The WilmerHale team representing Wellington Management consisted of Jason Kropp, Avery Reaves, Ashton Kennedy, Colleen Superko and Meghan Walsh.